In Discussion with Brian Culley, CEO of Lineage Cell Therapeutics

Welcome to the first episode of The Cancer Impact Network podcast series!

Our first guest is Brian Culley, CEO of Lineage Cell Therapeutics.  Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs such as dry AMD and patients with acute spinal cord injuries. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. Brian Culley discusses Lineage’s clinical programs in dry-AMD, spinal cord injury and cancer, markets with billion dollar opportunities. He also shares how Lineage is utilizing a novel hybrid approach of regenerative medicine in combination with allogeneic, or non-patient specific immune-mediated targeting of cancer cells. Their Phase 1 clinical trial for patients with non-small cell lung cancer (NSCLC) is currently underway and is being conducted by Cancer Research UK.

Brian Culley, M.Sc, MBA 
CEO, Lineage Cell Therapeutics 

In discussion with:
Himabindu Gaddipati, MD EMTM
CEO, Lumiseek Inc.